Device Trial Radar · NCT06512324
Operation of Brain Stimulation Equipment Under Remote Viewing Effectiveness Registry
Last checked: Nov 20, 2026Latest source record: Jul 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
5,000
Planned (sponsor's estimate)
Start
Jun 27, 2024
Primary completion
Aug 30, 2028
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- Biomedical Discoveries and Neuroscientific Foundations LLCNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jul 22, 2024
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this observational study is to record and analyze factors putatively affecting the clinical outcomes among patients undergoing transcranial magnetic stimulation (TMS) treatment for major depressive disorder (MDD) or generalized anxiety disorder (GAD). The main questions it aims to answer are: 1. Which factors have the greatest causal role in mediating the effectiveness of TMS in improving symptoms of depression (and/or anxiety)? 2. Which factors have a minimal causal role in mediating the effectiveness of TMS in improving symptoms of depression (and/or anxiety)? Participants already undergoing TMS as part of their treatment plan for MDD/GAD answer survey questions about their symptoms before, during, and up to 1 year post-treatment. Factors affecting clinical outcomes such as stimulation parameters, behavioral factors, physiological factors, patient characteristics, and pharmacological factors, are also recorded.
Conditions
- Major Depressive Disorder
- MDD
- Generalized Anxiety Disorder
- GAD
- Depression
- Anxiety
Interventions
Ampa One TMS SystemDevice
Transcranial Magnetic Stimulation
Primary outcomes
What the sponsor says the trial is designed to measure.
- 9-item Patient Health Questionnaire (PHQ-9) [or PHQ-9-A if appropriate]Time frame: Administered weekly from baseline up to 1 year from the end of treatment.
- 7-item General Anxiety Disorder Questionnaire (GAD-7) [or GAD-10-A if appropriate]Time frame: Administered weekly from baseline up to 1 year from the end of treatment.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Kind Health Group
Encinitas, California
Salience Research Institute
Plano, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.